Ribozyme, Eli Lilly deal

The companies will develop ribozyme therapeutics to treat hepatitis C virus (HCV) infection. RZYM could receive up to $38 million, including $9.2 million this year in initial fees, research and clinical trial funding, a $7.5 million equity investment by Lilly, and milestones. RZYM also is eligible for royalties. Lilly will receive exclusive worldwide commercialization rights to products resulting from the collaboration. ...